Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Newsable Asianet News on MSN1d
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings BeatEli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the ...
If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...
Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.
FY2024). The recent selloff of Eli Lilly, driven by short-term inventory dynamics for its obesity drug, looks overdone. Source: UBS (January 2025, proprietary source), emphasis added. Indeed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback